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OBJECTIVES: To establish a formula that estimates tumor volume in localized prostate cancer based on serum prostate specific 
antigen levels. One of the main prognostic variables in localized prostate cancer is tumor volume, which can be precisely defined 
only after prostate extirpation. The present study defines a simple method that allows for estimation of tumor volume before treat-
ment, which can help to establish a better therapeutic strategy for each patient.
METHODS: From 1997 to 2002, 735 patients with prostate cancer of stagesT1c-T2c without any previous treatment were submit-
ted to radical prostatectomy. Surgical specimens were evaluated by the same pathologist and the total tumor volume (in cc) and the 
relative tumor volume (as the percent of the total prostate volume) were determined using the grid morphometric method. Pretreat-
ment serum prostate specific antigen was correlated with tumor volume in each patient using a linear regression model.
RESULTS: There were positive correlations between the serum levels of prostate specific antigen and the total tumor volume in 
cc (p<0.001) and the relative tumor volume as a percentage (p<0.001). For each ng/ml unit increment of serum prostate specific 
antigen, there was a 0.302 cc increase in total tumor volume and a 0.7% increase in relative tumor volume. Total and percent tumor 
volume could be calculated, respectively, using the formulas Volume (cc) = 3.476 + 0.302 x PSA (ng/ml) and Volume (%) = 11.331 
+ 0.704 x prostate specific antigen (ng/ml).
CONCLUSIONS: Tumor volume in patients with prostate cancer can be determined before treatment based on the serum prostate 
specific antigen levels. 
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INTRODUCTION
Studies of prostate cancer and its prognostic factors 
are of high importance to public health. Prostate cancer is 
frequent in males, representing 40% of malignant neoplasias 
in men and affecting 17.1% of all men.1 Epidemiological 
data show that prostate cancer is the second leading cause 
of cancer–related mortality in men, with lung cancer ranking 
first.1
The clinical challenge in treating prostate adenocarcinoma 
is that only a small number of men will die from the disease. 
Therefore, it is necessary to establish criteria to distinguish 
between those cases that require treatment and those for 
whom routine management is a good choice.2 After prostate 
cancer is diagnosed, the main prognostic factors that define 
severity and disease evolution are the Gleason score of the 
biopsy, the level of prostate specific antigen (PSA) in the 
blood and tumor volume.3 The importance of tumor volume 
in the follow-up of prostate cancer patients was demonstrated 
in papers that related larger neoplasia volumes with 
characteristics that were indicative of a worse prognosis: 
capsular invasion, seminal vesicle invasion, a worse response 
to treatment and metastases to regional lymph nodes and 
bones.2-5 The imaging methods that are currently used to 
determine prostate cancer volume are inaccurate and do not 
reflect the real extent of the disease.6 Thus, establishing a 760
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method to estimate tumor volume soon after diagnosis would 
be of great clinical relevance and would improve patient 
treatment.
The objective of this study was to investigate whether 
it is possible to predict tumor volume in prostate cancer 
patients by initial measurements of the PSA level.
MATERIAL AND METHODS
A retrospective study was conducted with 788 patients who 
were diagnosed with prostate adenocarcinoma, with disease at 
the T1b-T2c clinical stage. These patients underwent radical 
prostatectomy performed by a single surgeon (M.S.) between 
1997 and 2002. The 53 patients who received preoperatory 
hormone therapy were excluded from this study; therefore, 
the final assessed group included 735 cases.
The patients’ ages ranged from 41 to 79 years, with a 
mean of 63 years. For this study, the highest preoperative 
serum PSA level measured by the Tandem-R method was 
used.9
The surgical specimens were fixed in formalin and 
the whole gland was subjected to a histological study 
according to the recommendations of Bostwick and Foster.7 
Tumor volume assessment was conducted with the aid of 
a grid, as described by Humphrey and Vollmer.8 During 
the microscopic examination, the areas of the gland that 
were infiltrated by tumor were outlined using a pen with 
permanent ink. The marked slides were then put on top of 
a grid and the percentage of squares that were occupied by 
the adenocarcinoma was calculated in relation to the whole 
area covered by the specimen. Thus, the tumor volume 
corresponded to the gland area occupied by the tumor and 
its absolute value was calculated by multiplying the tumor 
percentage by the gland’s total weight.
The relationship between PSA levels and tumor volume 
was plotted on a dispersion graph and it was quantified 
by calculating the Pearson’s correlation coefficient, with 
its respective 95% confidence interval (95%CI). A linear 
regression model was generated to describe the relationship 
between the two variables.
The primary objective of the present study was to relate 
serum PSA levels to the outcomes of absolute tumor volume 
(in cc) and relative tumor volume (percentage of the gland 
infiltrated by tumor).
RESULTS
As shown in Figure 1, a statistically significant 
correlation was observed between the tumor volume in cc 
and serum PSA levels (p<0.001). Likewise, as shown in 
Figure 2, a positive correlation was demonstrated between 
the percentage of tumor volume and serum PSA levels 
(p<0.001). A statistical analysis of the data plotted in Figure 
1 shows that, for each 1 ng/ml increment in serum PSA, the 
absolute tumor volume increases by 0.302 cc. The linear 
regression equation is:
Volume (cc) = 3.476 + 0.302 x PSA
The statistical analysis of the data plotted in Figure 2 
shows that, for each 1 ng/ml increment in serum PSA, there is 
an increase of 0.7% in the percent tumor volume in relation to 
the entire gland. The linear regression equation is:
Volume (%) = 11.331+ 0.704 x PSA
DISCUSSION
In a previous study we analyzed the risk factor for a 
prostate carcinoma in patients with benign hyperplasia.10 
In the present study, we demonstrate that, there is a direct 
relationship between PSA levels and tumor volume, both in 
terms of cc and tumor percentage, in patients with localized 
prostate cancer. Thus, it is possible to estimate tumor volume 
soon after disease diagnosis. This strategy would allow for 
more rational treatment planning for patients.
Figure 1 - Correlation between tumor volume (cc) and serum PSA levels
(Pearson’s correlation = 0.332 [IC 95% : 0.266 – 0.395], p<0.001)
Figure 2 - Correlation between relative tumor volume (%) and serum PSA 
levels (Pearson’s correlation = 0.289 [IC 95% : 0.221 – 0.354], p<0.001)761
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The results presented here had a high level of consistency 
due to the large number of patients examined and because 
the tumor volume assessment was performed by a single 
observer (K.L.). This study is limited by the fact that the 
PSA measurements for selected patients were performed in 
different laboratories.
In a study of 320 patients, by Blackwell et al.6 
demonstrated that preoperatory serum PSA levels were of 
great value in predicting not only the tumor volume, but also 
the pathological staging and risk of disease dissemination. 
Likewise, Bostwick and colleagues11-13 concluded that 
it is possible to predict tumor volume from initial PSA 
measurements. Partin and colleagues14 studied 56 patients 
who underwent radical prostatectomy and concluded that 
the percentage of the gland with tumor had higher predictive 
value than the absolute tumor volume when defining the 
pathological stage of the disease.
In contrast, after a five-year follow-up study of 185 
patients who underwent radical prostatectomy, Epstein and 
colleagues15 concluded that the tumor volume measurement 
should not be routine practice in surgical pathology as it 
does not contribute any additional information regarding 
disease progression. They suggested that the Gleason score 
is a sufficient parameter for disease progression.
The medical literature indicates that, while controversial, 
the assessment of tumor volume soon after disease diagnosis 
might help to better define the aggressiveness of the 
neoplasia.
According to the data presented here, it is possible to 
predict the tumor volume at the time of disease diagnosis 
and thus adequately select the appropriate treatment for 
each patient. If the tumor is of small volume, radical curative 
treatment or patient observation with clinical follow-up 
is recommended.16 In contrast, if the tumor is of large 
volume, exclusive or adjuvant systemic treatment should 
be considered due to the high risk of metastasis. According 
to McNeal and colleagues,17 62% of patients with tumor 
volumes larger than 16 cc presented with distant metastases, 
while patients with tumor volumes smaller than 4 cc 
presented with disease dissemination.
Thus, for those who value tumor volume estimates 
soon after diagnosis, the present study presents a simple 
mathematical instrument to calculate such a value, which 
may directly contribute to the selection of appropriate 
treatments for patients with prostate adenocarcinoma.
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